Seres Therapeutics, Inc. Loss Contingency Accrual
Seres Therapeutics, Inc. (MCRB) had Loss Contingency Accrual of $0 as of 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LossContingencyAccrualAtCarryingValue · last filed 2016-11-10
- 2016-09-30: Loss Contingency Accrual $0.00.
| Period end | Loss Contingency Accrual |
|---|---|
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |